Cecilia Chiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cecilia Chiu has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- James T. Koerber
Department of Antibody Engineering, Genentech, Inc., South San Francisco, USA
3 shared publications - WeiYu Lin
Antibody Engineering, Genentech, USA
3 shared publications - Yonglian Sun
Department of Antibody Engineering, Genentech, South San Francisco, CA, USA
2 shared publications - Zhaojun Yin
Department of Developmental Sciences BioAnalytical Sciences, Genentech, South San Francisco, CA, USA
2 shared publications Adeyemi O. Adedeji
Department of Developmental Sciences Translational Safety, Genentech, South San Francisco, CA, USA
1 shared publication- Aija Kusi
Department of Developmental Sciences Translational Safety, Genentech, South San Francisco, CA, USA
1 shared publication
Latest Publications
- 28 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (873)
T cell–mediated depletion of intratumoral regulatory T cells using a CCR8xCD3 T cell–engaging bispecific antibody (TCB) promotes antitumor immunity in preclinical mouse models
T cell–engaging bispecific antibodies (TCBs) have seen notable successes in hematologic malignancies, and emerging data demonstrate their potential for the treatment of solid tumors. Most oncology applications of TCBs have focused on targeting tumor cells via tumor-specific antigens; however, TCBs have been underutilized for strategic depletion of immunosuppressive cells in the TME. Regulatory T cells (T reg cells) play a crucial role in suppressing antitumor immune responses, making them an attractive target for immune-based therapies. T reg cells express several surface markers that can serve as potential targets for antibody-mediated depletion, including C-C chemokine receptor type 8 (CCR8), which is highly enriched on tumor-infiltrating T reg cells. Monoclonal antibody (mAb)–mediated T reg cell depletion relies on natural killer (NK) cells, which can be scarce in some solid tumors, whereas TCBs can broadly engage the T cell compartment by overwriting antigen specificity and redirecting potent T cell cytotoxicity against target cells. Here, we have developed a CCR8xCD3 TCB and show that it effectively depletes CCR8-expressing T reg cells in a T cell–mediated manner. CCR8xCD3 TCB led to the selective depletion of intratumoral T reg cells from human solid tumor samples in vitro and mediated inhibition of tumor growth in multiple syngeneic tumor models with variable levels of T cell infiltration alone or in combination with anti–PD-L1. In cynomolgus monkeys, CCR8xCD3 TCB was well tolerated without evidence of acute phase inflammation or cytokine release syndrome and led to effective and durable depletion of the CCR8-expressing subset of T reg cells.
- 28 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (873)
T cell–mediated depletion of intratumoral regulatory T cells using a CCR8xCD3 T cell–engaging bispecific antibody (TCB) promotes antitumor immunity in preclinical mouse models
T cell–engaging bispecific antibodies (TCBs) have seen notable successes in hematologic malignancies, and emerging data demonstrate their potential for the treatment of solid tumors. Most oncology applications of TCBs have focused on targeting tumor cells via tumor-specific antigens; however, TCBs have been underutilized for strategic depletion of immunosuppressive cells in the TME. Regulatory T cells (T reg cells) play a crucial role in suppressing antitumor immune responses, making them an attractive target for immune-based therapies. T reg cells express several surface markers that can serve as potential targets for antibody-mediated depletion, including C-C chemokine receptor type 8 (CCR8), which is highly enriched on tumor-infiltrating T reg cells. Monoclonal antibody (mAb)–mediated T reg cell depletion relies on natural killer (NK) cells, which can be scarce in some solid tumors, whereas TCBs can broadly engage the T cell compartment by overwriting antigen specificity and redirecting potent T cell cytotoxicity against target cells. Here, we have developed a CCR8xCD3 TCB and show that it effectively depletes CCR8-expressing T reg cells in a T cell–mediated manner. CCR8xCD3 TCB led to the selective depletion of intratumoral T reg cells from human solid tumor samples in vitro and mediated inhibition of tumor growth in multiple syngeneic tumor models with variable levels of T cell infiltration alone or in combination with anti–PD-L1. In cynomolgus monkeys, CCR8xCD3 TCB was well tolerated without evidence of acute phase inflammation or cytokine release syndrome and led to effective and durable depletion of the CCR8-expressing subset of T reg cells.
- Open Access
- 23 December 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (1) , 41
Revisiting the Anti-Drug Antibody Assay Drug Tolerance of a Commercial Biological Product
Drug tolerance (DT) is a critical attribute of anti-drug antibody (ADA) assays for assessing clinical immunogenicity. We present a unique situation where a previously approved commercial product, atezolizumab, required re-assessment of the assay DT to meet an increased drug exposure demand arising from a new route of administration (subcutaneous) and align with updated health authority (HA) regulations. Rather than redevelop the existing ADA assay, which could disrupt ongoing clinical trials, we identified a new anti-idiotype (anti-ID) antibody surrogate that demonstrated that the assay maintained adequate DT for the new route of administration. This streamlined approach addressed concerns regarding higher serum trough concentrations with subcutaneous administration and stricter sensitivity expectations. We established a target DT concentration based on population pharmacokinetic modeling to ensure adequate ADA characterization at steady state. This case study highlights the value of having alternative surrogate ADAs and demonstrates that achieving stringent DT requirements can be accomplished without extensive method redevelopment. We also introduce the broader implications of surrogate ADA selection, binding kinetics, and the clinical relevance of achieving high DT in the context of atezolizumab's efficacy and safety profile. This work also emphasizes the importance of considering bioanalytical assay characteristics, such as DT, throughout a product’s lifecycle. Graphical Abstract
- 23 December 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (1) , 41
Open AccessRevisiting the Anti-Drug Antibody Assay Drug Tolerance of a Commercial Biological Product
Drug tolerance (DT) is a critical attribute of anti-drug antibody (ADA) assays for assessing clinical immunogenicity. We present a unique situation where a previously approved commercial product, atezolizumab, required re-assessment of the assay DT to meet an increased drug exposure demand arising from a new route of administration (subcutaneous) and align with updated health authority (HA) regulations. Rather than redevelop the existing ADA assay, which could disrupt ongoing clinical trials, we identified a new anti-idiotype (anti-ID) antibody surrogate that demonstrated that the assay maintained adequate DT for the new route of administration. This streamlined approach addressed concerns regarding higher serum trough concentrations with subcutaneous administration and stricter sensitivity expectations. We established a target DT concentration based on population pharmacokinetic modeling to ensure adequate ADA characterization at steady state. This case study highlights the value of having alternative surrogate ADAs and demonstrates that achieving stringent DT requirements can be accomplished without extensive method redevelopment. We also introduce the broader implications of surrogate ADA selection, binding kinetics, and the clinical relevance of achieving high DT in the context of atezolizumab's efficacy and safety profile. This work also emphasizes the importance of considering bioanalytical assay characteristics, such as DT, throughout a product’s lifecycle. Graphical Abstract
- 1 October 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1-14
A Fit-for-purpose Strategy for Clinical Immunogenicity Assessment of Multivalent Bispecific Antibodies
Bispecific antibodies (BsAbs) have emerged as a promising class of therapeutics to treat complex diseases, offering advantages in dual targeting simultaneo
- 1 October 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1-14
A Fit-for-purpose Strategy for Clinical Immunogenicity Assessment of Multivalent Bispecific Antibodies
Bispecific antibodies (BsAbs) have emerged as a promising class of therapeutics to treat complex diseases, offering advantages in dual targeting simultaneo
- Open Access
Rational design of oxidation-resistant antibodies through local electrostatic modulation
Oxidation is a significant degradation pathway in proteins, particularly therapeutic antibodies, that can impair function, efficacy, and stability. Understanding the sequence and structural factors that drive oxidation susceptibility is critical for incorporating chemical stability into early-stage antibody design. Here, we present a machine learning classifier trained on expert-guided structural features to assess tryptophan (Trp) oxidation risks in the complementarity-determining regions (CDR) of 187 antibodies produced internally at Genentech. The model reveals a strong correlation between local negative electrostatic potential and Trp oxidation susceptibility. A simplified two-parameter model derived from these insights achieves 79% accuracy in classifying oxidation risk, compared to 84% accuracy with the full-feature classifier. Beyond our internal dataset, the two-parameter model successfully predicted oxidation risk for all CDR Trp sites in a blind subset of eight clinical-stage antibodies. In addition, we show that modulating the electrostatic potential around the Trp side-chains through distant charge-altering mutations can significantly reduce oxidation rates. In four out of five re-engineered antibodies, oxidation rates decreased by approximately 50%, while half of these maintained binding affinity. Finally, we demonstrate that this approach can guide multi-property optimization by balancing oxidation resistance and affinity in an anti-CD33 antibody. These results establish a strong link between local electrostatic environments and Trp oxidation susceptibility, and provide a practical framework for designing oxidation resistant biotherapeutics.
Open AccessRational design of oxidation-resistant antibodies through local electrostatic modulation
Oxidation is a significant degradation pathway in proteins, particularly therapeutic antibodies, that can impair function, efficacy, and stability. Understanding the sequence and structural factors that drive oxidation susceptibility is critical for incorporating chemical stability into early-stage antibody design. Here, we present a machine learning classifier trained on expert-guided structural features to assess tryptophan (Trp) oxidation risks in the complementarity-determining regions (CDR) of 187 antibodies produced internally at Genentech. The model reveals a strong correlation between local negative electrostatic potential and Trp oxidation susceptibility. A simplified two-parameter model derived from these insights achieves 79% accuracy in classifying oxidation risk, compared to 84% accuracy with the full-feature classifier. Beyond our internal dataset, the two-parameter model successfully predicted oxidation risk for all CDR Trp sites in a blind subset of eight clinical-stage antibodies. In addition, we show that modulating the electrostatic potential around the Trp side-chains through distant charge-altering mutations can significantly reduce oxidation rates. In four out of five re-engineered antibodies, oxidation rates decreased by approximately 50%, while half of these maintained binding affinity. Finally, we demonstrate that this approach can guide multi-property optimization by balancing oxidation resistance and affinity in an anti-CD33 antibody. These results establish a strong link between local electrostatic environments and Trp oxidation susceptibility, and provide a practical framework for designing oxidation resistant biotherapeutics.
- 14 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (675) , eabp9159
Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis
The epidermis is a barrier that prevents water loss while keeping harmful substances from penetrating the host. The impermeable cornified layer of the stratum corneum is maintained by balancing continuous turnover driven by epidermal basal cell proliferation, suprabasal cell differentiation, and corneal shedding. The epidermal desquamation process is tightly regulated by balance of the activities of serine proteases of the Kallikrein-related peptidases (KLK) family and their cognate inhibitor lymphoepithelial Kazal type–related inhibitor (LEKTI), which is encoded by the serine peptidase inhibitor Kazal type 5 gene. Imbalance of proteolytic activity caused by a deficiency of LEKTI leads to excessive desquamation due to increased activities of KLK5, KLK7, and KLK14 and results in Netherton syndrome (NS), a debilitating condition with an unmet clinical need. Increased activity of KLKs may also be pathological in other dermatoses such as atopic dermatitis (AD). Here, we describe the discovery of inhibitory antibodies against murine KLK5 and KLK7 that could compensate for the deficiency of LEKTI in NS. These antibodies are protective in mouse models of NS and AD and, when combined, promote improved skin barrier integrity and reduced inflammation. To translate these findings, we engineered a humanized bispecific antibody capable of potent inhibition of human KLK5 and KLK7. A crystal structure of KLK5 bound to the inhibitory Fab revealed that the antibody binds distal to its active site and uses a relatively unappreciated allosteric inhibition mechanism. Treatment with the bispecific anti-KLK5/7 antibody represents a promising therapy for clinical development in NS and other inflammatory dermatoses.
- 14 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (675) , eabp9159
Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis
The epidermis is a barrier that prevents water loss while keeping harmful substances from penetrating the host. The impermeable cornified layer of the stratum corneum is maintained by balancing continuous turnover driven by epidermal basal cell proliferation, suprabasal cell differentiation, and corneal shedding. The epidermal desquamation process is tightly regulated by balance of the activities of serine proteases of the Kallikrein-related peptidases (KLK) family and their cognate inhibitor lymphoepithelial Kazal type–related inhibitor (LEKTI), which is encoded by the serine peptidase inhibitor Kazal type 5 gene. Imbalance of proteolytic activity caused by a deficiency of LEKTI leads to excessive desquamation due to increased activities of KLK5, KLK7, and KLK14 and results in Netherton syndrome (NS), a debilitating condition with an unmet clinical need. Increased activity of KLKs may also be pathological in other dermatoses such as atopic dermatitis (AD). Here, we describe the discovery of inhibitory antibodies against murine KLK5 and KLK7 that could compensate for the deficiency of LEKTI in NS. These antibodies are protective in mouse models of NS and AD and, when combined, promote improved skin barrier integrity and reduced inflammation. To translate these findings, we engineered a humanized bispecific antibody capable of potent inhibition of human KLK5 and KLK7. A crystal structure of KLK5 bound to the inhibitory Fab revealed that the antibody binds distal to its active site and uses a relatively unappreciated allosteric inhibition mechanism. Treatment with the bispecific anti-KLK5/7 antibody represents a promising therapy for clinical development in NS and other inflammatory dermatoses.
- Open Access
- 1 April 2022
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 21 (6) , 974-985
Novel Anti-LY6G6D/CD3 T-Cell–Dependent Bispecific Antibody for the Treatment of Colorectal Cancer
New therapeutics and combination regimens have led to marked clinical improvements for the treatment of a subset of colorectal cancer. Immune checkpoint inhibitors have shown clinical efficacy in patients with mismatch-repair–deficient or microsatellite instability–high (MSI-H) metastatic colorectal cancer (mCRC). However, patients with microsatellite-stable (MSS) or low levels of microsatellite instable (MSI-L) colorectal cancer have not benefited from these immune modulators, and the survival outcome remains poor for the majority of patients diagnosed with mCRC. In this article, we describe the discovery of a novel T-cell–dependent bispecific antibody (TDB) targeting tumor-associated antigen LY6G6D, LY6G6D-TDB, for the treatment of colorectal cancer. RNAseq analysis showed that LY6G6D was differentially expressed in colorectal cancer with high prevalence in MSS and MSI-L subsets, whereas LY6G6D expression in normal tissues was limited. IHC confirmed the elevated expression of LY6G6D in primary and metastatic colorectal tumors, whereas minimal or no expression was observed in most normal tissue samples. The optimized LY6G6D-TDB, which targets a membrane-proximal epitope of LY6G6D and binds to CD3 with high affinity, exhibits potent antitumor activity both in vitro and in vivo. In vitro functional assays show that LY6G6D-TDB–mediated T-cell activation and cytotoxicity are conditional and target dependent. In mouse xenograft tumor models, LY6G6D-TDB demonstrates antitumor efficacy as a single agent against established colorectal tumors, and enhanced efficacy can be achieved when LY6G6D-TDB is combined with PD-1 blockade. Our studies provide evidence for the therapeutic potential of LY6G6D-TDB as an effective treatment option for patients with colorectal cancer.
- 1 April 2022
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 21 (6) , 974-985
Open AccessNovel Anti-LY6G6D/CD3 T-Cell–Dependent Bispecific Antibody for the Treatment of Colorectal Cancer
New therapeutics and combination regimens have led to marked clinical improvements for the treatment of a subset of colorectal cancer. Immune checkpoint inhibitors have shown clinical efficacy in patients with mismatch-repair–deficient or microsatellite instability–high (MSI-H) metastatic colorectal cancer (mCRC). However, patients with microsatellite-stable (MSS) or low levels of microsatellite instable (MSI-L) colorectal cancer have not benefited from these immune modulators, and the survival outcome remains poor for the majority of patients diagnosed with mCRC. In this article, we describe the discovery of a novel T-cell–dependent bispecific antibody (TDB) targeting tumor-associated antigen LY6G6D, LY6G6D-TDB, for the treatment of colorectal cancer. RNAseq analysis showed that LY6G6D was differentially expressed in colorectal cancer with high prevalence in MSS and MSI-L subsets, whereas LY6G6D expression in normal tissues was limited. IHC confirmed the elevated expression of LY6G6D in primary and metastatic colorectal tumors, whereas minimal or no expression was observed in most normal tissue samples. The optimized LY6G6D-TDB, which targets a membrane-proximal epitope of LY6G6D and binds to CD3 with high affinity, exhibits potent antitumor activity both in vitro and in vivo. In vitro functional assays show that LY6G6D-TDB–mediated T-cell activation and cytotoxicity are conditional and target dependent. In mouse xenograft tumor models, LY6G6D-TDB demonstrates antitumor efficacy as a single agent against established colorectal tumors, and enhanced efficacy can be achieved when LY6G6D-TDB is combined with PD-1 blockade. Our studies provide evidence for the therapeutic potential of LY6G6D-TDB as an effective treatment option for patients with colorectal cancer.
- Open Access
- 27 July 2021
- Published by Springer Nature in Communications Biology
- Vol. 4 (1) , 1-16
Structures of the ApoL1 and ApoL2 N-terminal domains reveal a non-classical four-helix bundle motif
Apolipoprotein L1 (ApoL1) is a circulating innate immunity protein protecting against trypanosome infection. However, two ApoL1 coding variants are associated with a highly increased risk of chronic kidney disease. Here we present X-ray and NMR structures of the N-terminal domain (NTD) of ApoL1 and of its closest relative ApoL2. In both proteins, four of the five NTD helices form a four-helix core structure which is different from the classical four-helix bundle and from the pore-forming domain of colicin A. The reactivity with a conformation-specific antibody and structural models predict that this four-helix motif is also present in the NTDs of ApoL3 and ApoL4, suggesting related functions within the small ApoL family. The long helix 5 of ApoL1 is conformationally flexible and contains the BH3-like region. This BH3-like α-helix resembles true BH3 domains only in sequence and structure but not in function, since it does not bind to the pro-survival members of the Bcl-2 family, suggesting a Bcl-2-independent role in cytotoxicity. These findings should expedite a more comprehensive structural and functional understanding of the ApoL immune protein family.
- 27 July 2021
- Published by Springer Nature in Communications Biology
- Vol. 4 (1) , 1-16
Open AccessStructures of the ApoL1 and ApoL2 N-terminal domains reveal a non-classical four-helix bundle motif
Apolipoprotein L1 (ApoL1) is a circulating innate immunity protein protecting against trypanosome infection. However, two ApoL1 coding variants are associated with a highly increased risk of chronic kidney disease. Here we present X-ray and NMR structures of the N-terminal domain (NTD) of ApoL1 and of its closest relative ApoL2. In both proteins, four of the five NTD helices form a four-helix core structure which is different from the classical four-helix bundle and from the pore-forming domain of colicin A. The reactivity with a conformation-specific antibody and structural models predict that this four-helix motif is also present in the NTDs of ApoL3 and ApoL4, suggesting related functions within the small ApoL family. The long helix 5 of ApoL1 is conformationally flexible and contains the BH3-like region. This BH3-like α-helix resembles true BH3 domains only in sequence and structure but not in function, since it does not bind to the pro-survival members of the Bcl-2 family, suggesting a Bcl-2-independent role in cytotoxicity. These findings should expedite a more comprehensive structural and functional understanding of the ApoL immune protein family.